FIELD: pharmacology.
SUBSTANCE: invention refers to pharmacology, namely to drugs possessing antidepressant activity. What is presented is the use of gaulterin as an antidepressant.
EFFECT: invention makes it possible to increase efficiency of therapeutic action and to exclude occurrence of side effects.
9 cl, 1 dwg, 1 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
USE OF PATULYTHRIN AS AN ANTIDEPRESSANT | 2022 |
|
RU2802977C1 |
USE OF CYNAROSIDE HAVING NEUROTROPIC ACTIVITY | 2023 |
|
RU2832839C1 |
USE OF SALICIN HAVING NEUROTROPIC ACTIVITY | 2023 |
|
RU2832938C1 |
USE OF APIGENIN HAVING NEUROTROPIC ACTIVITY | 2023 |
|
RU2832841C1 |
USE OF ISORHAMNETIN 3-O-β-D-GLUCOPYRANOSIDE, HAVING NEUROTROPIC ACTIVITY | 2024 |
|
RU2833215C1 |
USE OF OREGANOL A WITH NEUROTROPIC ACTIVITY | 2022 |
|
RU2802871C1 |
USE OF COSMOSIIN HAVING NEUROTROPIC ACTIVITY | 2023 |
|
RU2833214C1 |
ANTIDEPRESSANT FOR CORRECTION OF SIDE EFFECTS FROM NEUROLEPTICS | 2019 |
|
RU2746012C2 |
ANTIDEPRESSANT, ANXIOLYTIC, NEUROPROTECTIVE AND IMMUNOSTIMULATING AGENT | 2010 |
|
RU2429834C1 |
9-[2-(4-ISOPROPYLPHENOXY)ETHYL]ADENINE POSSESSING ANTIDEPRESSANT AND STRESS-RELIEVING ACTION | 2013 |
|
RU2529817C1 |
Authors
Dates
2024-08-26—Published
2023-12-31—Filed